nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ibandronate—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ibandronate—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Ibandronate—Haemoglobin—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Ibandronate—Urticaria—Teniposide—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Ibandronate—Haemorrhage—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Ibandronate—Body temperature increased—Teniposide—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Ibandronate—Abdominal pain—Teniposide—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Ibandronate—Erythema—Bleomycin—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Ibandronate—Paraesthesia—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Ibandronate—Sweating—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Ibandronate—Oedema peripheral—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Ibandronate—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Ibandronate—Dyspepsia—Fludarabine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Ibandronate—Ulcer—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Ibandronate—Decreased appetite—Fludarabine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ibandronate—Fatigue—Fludarabine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ibandronate—Inflammation—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ibandronate—Pain—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ibandronate—Constipation—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ibandronate—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Ibandronate—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ibandronate—Urethral disorder—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ibandronate—Eye disorder—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Ibandronate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Ibandronate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Ibandronate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Ibandronate—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Ibandronate—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Ibandronate—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Ibandronate—Anaemia—Bleomycin—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Ibandronate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Ibandronate—Asthenia—Teniposide—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Ibandronate—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ibandronate—Malaise—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ibandronate—Pruritus—Teniposide—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ibandronate—Cystitis—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ibandronate—Cardiac disorder—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Ibandronate—Alopecia—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Ibandronate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Mental disorder—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Ibandronate—Vaginal infection—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Ibandronate—Malnutrition—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Ibandronate—Erythema—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Ibandronate—Angiopathy—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ibandronate—Diarrhoea—Teniposide—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Ibandronate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Ibandronate—Chest pain—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Ibandronate—Myalgia—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Ibandronate—Alopecia—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Ibandronate—Back pain—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Ibandronate—Discomfort—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Ibandronate—Mental disorder—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ibandronate—Chills—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ibandronate—Bladder pain—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ibandronate—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ibandronate—Ecchymosis—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ibandronate—Alopecia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Ibandronate—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Ibandronate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Ibandronate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Ibandronate—Erythema—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Ibandronate—Infection—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Ibandronate—Anaemia—Carmustine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Ibandronate—Back pain—Vincristine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Ibandronate—Vomiting—Teniposide—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Ibandronate—Asthenia—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ibandronate—Rash—Teniposide—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ibandronate—Dermatitis—Teniposide—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ibandronate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ibandronate—Headache—Teniposide—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ibandronate—Pruritus—Fludarabine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Ibandronate—Back pain—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Ibandronate—Anaemia—Vincristine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Ibandronate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Ibandronate—Hypertension—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ibandronate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ibandronate—Nausea—Teniposide—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ibandronate—Anaemia—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ibandronate—Vertigo—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Ibandronate—Myalgia—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Ibandronate—Chest pain—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Ibandronate—Anxiety—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Ibandronate—Paraesthesia—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Ibandronate—Malaise—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Ibandronate—Renal failure acute—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Ibandronate—Hypertension—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Ibandronate—Decreased appetite—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Myalgia—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Infection—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Vomiting—Fludarabine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ibandronate—Rash—Fludarabine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Ibandronate—Dermatitis—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ibandronate—Hypertension—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ibandronate—Pain—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ibandronate—Headache—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Ibandronate—Myalgia—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ibandronate—Chest pain—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ibandronate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ibandronate—Anxiety—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Ibandronate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ibandronate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Ibandronate—Infection—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Ibandronate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Ibandronate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Ibandronate—Nervous system disorder—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ibandronate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Ibandronate—Nausea—Fludarabine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Ibandronate—Infection—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Ibandronate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Ibandronate—Shock—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Ibandronate—Urticaria—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ibandronate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ibandronate—Insomnia—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ibandronate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ibandronate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Paraesthesia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Ibandronate—Decreased appetite—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Ibandronate—Insomnia—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Ibandronate—Paraesthesia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ibandronate—Pain—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ibandronate—Constipation—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ibandronate—Breast disorder—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ibandronate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ibandronate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Ibandronate—Decreased appetite—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Feeling abnormal—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Fatigue—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Asthenia—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ibandronate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Pain—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Constipation—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Asthma—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ibandronate—Pruritus—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Ibandronate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Ibandronate—Fatigue—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ibandronate—Pain—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Constipation—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Ibandronate—Abdominal pain—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Ibandronate—Body temperature increased—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ibandronate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ibandronate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ibandronate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Ibandronate—Body temperature increased—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Ibandronate—Abdominal pain—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Ibandronate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Vomiting—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ibandronate—Infestation—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ibandronate—Depression—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ibandronate—Rash—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ibandronate—Dermatitis—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Ibandronate—Asthenia—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ibandronate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ibandronate—Sweating—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Asthenia—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Diarrhoea—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ibandronate—Nausea—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ibandronate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Ibandronate—Dizziness—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Ibandronate—Diarrhoea—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ibandronate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ibandronate—Vomiting—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ibandronate—Dizziness—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ibandronate—Rash—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Dermatitis—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Headache—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ibandronate—Vomiting—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ibandronate—Rash—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ibandronate—Dermatitis—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ibandronate—Headache—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ibandronate—Nausea—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ibandronate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Rash—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ibandronate—Chills—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ibandronate—Headache—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ibandronate—Erythema—Methotrexate—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Ibandronate—Nausea—Vincristine—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Ibandronate—Nausea—Mitoxantrone—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Ibandronate—Back pain—Methotrexate—lymphatic system cancer	0.000962	0.000962	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000922	0.000922	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—lymphatic system cancer	0.000919	0.000919	CcSEcCtD
Ibandronate—Malaise—Methotrexate—lymphatic system cancer	0.000897	0.000897	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Ibandronate—Infection—Methotrexate—lymphatic system cancer	0.000806	0.000806	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000796	0.000796	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000739	0.000739	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—lymphatic system cancer	0.000734	0.000734	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000714	0.000714	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Ibandronate—Pain—Methotrexate—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—lymphatic system cancer	0.000645	0.000645	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000598	0.000598	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—lymphatic system cancer	0.000574	0.000574	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—lymphatic system cancer	0.000516	0.000516	CcSEcCtD
Ibandronate—Rash—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Ibandronate—Headache—Methotrexate—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Ibandronate—Nausea—Methotrexate—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
